Sera Prognostics Stock Today
| SERA Stock | USD 4.14 0.06 1.47% |
PerformanceVery Weak
| Odds Of DistressLow
|
Sera Prognostics is trading at 4.14 as of the 19th of March 2025, a 1.47 percent increase since the beginning of the trading day. The stock's open price was 4.08. Sera Prognostics has about a 20 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 19th of December 2024 and ending today, the 19th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 15th of July 2021 | Category Healthcare | Classification Health Care |
Sera Prognostics, Inc., a womens health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah. Sera Prognostics operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. The company has 34.05 M outstanding shares of which 821.12 K shares are at this time shorted by private and institutional investors with about 6.15 trading days to cover. More on Sera Prognostics
Moving together with Sera Stock
Moving against Sera Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Sera Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO President | Evguenia MBA | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Diagnostics & Research, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsSera Prognostics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Sera Prognostics' financial leverage. It provides some insight into what part of Sera Prognostics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sera Prognostics (SERA) is traded on NASDAQ Exchange in USA. It is located in 2749 East Parleys Way, Salt Lake City, UT, United States, 84109 and employs 55 people. Sera Prognostics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 144.99 M. Sera Prognostics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 34.05 M outstanding shares of which 821.12 K shares are at this time shorted by private and institutional investors with about 6.15 trading days to cover.
Sera Prognostics currently holds about 106.91 M in cash with (27.19 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.45.
Check Sera Prognostics Probability Of Bankruptcy
Ownership AllocationSera Prognostics shows a total of 34.05 Million outstanding shares. Over half of Sera Prognostics' outstanding shares are owned by institutional holders. These institutional holders are typically referred to as corporate investors that take positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Sera Ownership Details
Sera Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Morgan Stanley - Brokerage Accounts | 2024-12-31 | 181.5 K | |
| Goldman Sachs Group Inc | 2024-12-31 | 141 K | |
| Bank Of New York Mellon Corp | 2024-12-31 | 130.9 K | |
| Susquehanna International Group, Llp | 2024-12-31 | 102.5 K | |
| Smh Capital Inc. | 2024-12-31 | 90.6 K | |
| Bridgeway Capital Management, Llc | 2024-12-31 | 87.8 K | |
| Charles Schwab Investment Management Inc | 2024-12-31 | 81.2 K | |
| Perigon Wealth Management, Llc | 2024-12-31 | 72.7 K | |
| Millennium Management Llc | 2024-12-31 | 70.7 K | |
| Baker Bros Advisors Lp | 2024-12-31 | 5.4 M | |
| Ra Capital Management, Llc | 2024-12-31 | 3 M |
Sera Prognostics Historical Income Statement
Sera Stock Against Markets
Sera Prognostics Corporate Management
| Benjamin JD | General Counsel | Profile | |
| Steven Graves | CoFounder Board | Profile | |
| Sean MD | CoFounder Board | Profile | |
| John Boniface | Chief Officer | Profile | |
| Paul Kearney | Chief Officer | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sera Prognostics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Sera Stock refer to our How to Trade Sera Stock guide.You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sera Prognostics. If investors know Sera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sera Prognostics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.99) | Revenue Per Share | Quarterly Revenue Growth (0.31) | Return On Assets | Return On Equity |
The market value of Sera Prognostics is measured differently than its book value, which is the value of Sera that is recorded on the company's balance sheet. Investors also form their own opinion of Sera Prognostics' value that differs from its market value or its book value, called intrinsic value, which is Sera Prognostics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sera Prognostics' market value can be influenced by many factors that don't directly affect Sera Prognostics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sera Prognostics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sera Prognostics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sera Prognostics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.